Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Non Operating Income (2018 - 2025)

Historic Non Operating Income for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $4.3 million.

  • 10x Genomics' Non Operating Income rose 19801.23% to $4.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.1 million, marking a year-over-year increase of 2502.52%. This contributed to the annual value of $21.1 million for FY2025, which is 2502.52% up from last year.
  • As of Q4 2025, 10x Genomics' Non Operating Income stood at $4.3 million, which was up 19801.23% from $4.0 million recorded in Q3 2025.
  • 10x Genomics' Non Operating Income's 5-year high stood at $10.2 million during Q4 2022, with a 5-year trough of -$2.0 million in Q3 2022.
  • Moreover, its 5-year median value for Non Operating Income was $2.8 million (2023), whereas its average is $3.0 million.
  • Over the last 5 years, 10x Genomics' Non Operating Income had its largest YoY gain of 633680.98% in 2022, and its largest YoY loss of 45374.28% in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' Non Operating Income stood at -$163000.0 in 2021, then surged by 6336.81% to $10.2 million in 2022, then fell by 15.5% to $8.6 million in 2023, then crashed by 83.02% to $1.5 million in 2024, then surged by 198.01% to $4.3 million in 2025.
  • Its Non Operating Income stands at $4.3 million for Q4 2025, versus $4.0 million for Q3 2025 and $6.9 million for Q2 2025.